| Literature DB >> 28096975 |
Regev Cohen1, Frida Babushkin2, Shoshana Cohen2, Marina Afraimov2, Maurice Shapiro3, Martina Uda3, Efrat Khabra4, Amos Adler5, Ronen Ben Ami6, Svetlana Paikin7.
Abstract
BACKGROUND: Pseudomonas aeruginosa (PA) surveillance may improve empiric antimicrobial therapy, since colonizing strains frequently cause infections. This colonization may be 'endogenous' or 'exogenous', and the source determines infection control measures. We prospectively investigated the sources of PA, the clinical impact of PA colonization upon admission and the dynamics of colonization at different body sites throughout the intensive care unit stay.Entities:
Keywords: ERIC-PCR; Endogenous; Infection control; Intensive Care unit; Pseudomonas aeruginosa; Surveillance
Year: 2017 PMID: 28096975 PMCID: PMC5225573 DOI: 10.1186/s13756-016-0167-7
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Fig. 1Study population
Patient characteristics according to P. aeruginosa carriage status on ICU admission
| All patients ( | Negative on admission ( | Positive on admission ( | P (OR, 95% CI) | |
|---|---|---|---|---|
| Age mean (range) | 70.3 (15-96) | 65.6 (15-96) | 79.3 (45-94) | 0.0039 |
| Age over 70 years | 22 (58%) | 11 (44%) | 11 (84%) | 0.035 (7, 1.2-38.3) |
| Sex | ||||
| Male | 22 (58) | 16 (64) | 6 (46) | 0.52 |
| Female | 16 (42) | 9 (36) | 7 (54) | 0.52 |
| LTCF residency | 3 (8) | 0 | 3 (23) | 0.033 (17, 0.8-358) |
| APACHE II score, mean (range) | 21.4 (10-42) | 21.0 (10-42) | 22.1 (14-34) | 0.66 |
| Days in hospital until ICU admission, mean (range) | 3.7 (0-22) | 3.7 (0-22) | 3.7 (0-11) | 0.98 |
| Hospitalization in the last 90 days | 19 (50) | 11 (44) | 8 (61) | 0.49 |
| Surgery in the last 30 days | 14 (37) | 8 (32) | 6 (46) | 0.48 |
| Antimicrobials in the last 90 days | 17 (45) | 12 (48) | 5 (38) | 0.73 |
| Prior PA in last 90 days | 3 (8) | 1 (4) | 2 (15) | 0.26 |
| ICU LOS, mean (range) | 15 (3-62) | 10.6 (3-39) | 23.7 (5-62) | 0.0338 |
| Hospital LOS, mean (range) | 28 (6-88) | 25 (6-80) | 33.7 (10-88) | 0.14 |
| Ventilation days in ICU, mean (range) | 17.3 (0-88) | 12.8 (0-79) | 26 (0-88) | 0.16 |
| COPD | 11 (29) | 7 (28) | 4 (31) | 1 |
| IHD | 15 (39) | 8 (32) | 7 (54) | 0.29 |
| CHF | 14 (37) | 7 (28) | 7 (54) | 0.16 |
| Past CVA | 9 (24) | 6 (24) | 3 (23) | 1 |
| CRF | 8 (21) | 5 (20) | 3 (23) | 1 |
| Immunosuppression | 4 (10) | 4 (16) | 0 | 0.27 |
| Dementia | 4 (10) | 1 (4) | 3 (23) | 0.1 |
| Active malignancy | 4 (10) | 3 (12) | 1 (7) | 1 |
| DM type 2 | 15 (39) | 14 (56) | 1 (7) | 0.005 (0.06, 0.007-0.58) |
| Tracheostomy in ICU | 12 (31) | 6 (24) | 6 (46) | 0.27 |
| ICU death | 5 (13) | 2 (8) | 3 (23) | 0.31 |
| Overall death | 13 (34) | 8 (32) | 5 (38) | 0.7 |
All numbers represent patients (percent), unless specified otherwise. LTCF long term care facility, APACHE, acute physiology and chronic health evaluation, ICU Intensive care unit, PA P. aeruginosa, LOS length of stay, COPD chronic obstructive pulmonary disease, IHD ischemic heart disease, CHF congestive heart failure, CVA cerebrovascular accident, CRF chronic renal failure, DM diabetes mellitus, VAP ventilator associated pneumonia, CLABSI central line associated blood stream infection, CAUTI catheter associated urinary tract infection, OR odds ratio, CI confidence interval
P. aeruginosa colonization during ICU stay in 4 screening sites
| Any site (%) | Pharynx (%) | EA (%) | Urine (%) | Rectum (%) | |
|---|---|---|---|---|---|
| Admission screening ( | 13 (34) | 3 (23) | 6 (46) | 1 (7) | 10 (77) |
| Week 1 ( | 11 (52) | 5 (45) | 3 (27) | 0 (0) | 10 (91) |
| Week 2 ( | 6 (75) | 4 (66) | 3 (50) | 0 (0) | 6 (100) |
| Week 3 ( | 5 (71) | 4 (80) | 4 (80) | 1 (20) | 4 (80) |
| Week 4 ( | 2 (50) | 0 (0) | 0 (0) | 0 (0) | 2 (100) |
| Week 5 ( | 1 (50) | 1 (100) | 1 (100) | 0 (0) | 1 (100) |
| Week 6 ( | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
ICU intensive care unit, EA endotracheal aspirate
Fig. 2P. aeruginosa ERIC-PCR strains among 23 positive patients
Fig. 3Kaplan-Meier survival curves, comparing PA-related outcomes between positive and negative patients on admission
Concordance between screening and clinical ERIC-PCR strains
| Patient number | Screening culture strain | Site of screening | Clinical culture strain | Clinical culture site | Timing between screen and clinical culture | |
|---|---|---|---|---|---|---|
| Correlated cases | 1 | B1 | EA, P | B1 | Wound | Same week |
| 2 | A | Rc | A | EA | Same week | |
| Rc | Urine | 1 week | ||||
| EA, P, Rc | Same week | |||||
| 4 | D2 | Rc | D1 | Abdomen | Same week | |
| K1 | Rc | K2 | EA | 2 weeks | ||
| B2 | Rc | B2 | Urine | Same week | ||
| 6 | E2 | EA, P | E1 | EA | Same week | |
| 7 | I1, I2 | EA, P | I1 | EA | Same week | |
| 8 | G | Rc | G | Blood | 3 weeks | |
| EA, P, Rc | 2 weeks | |||||
| EA, P, Rc | 1 week | |||||
| EA, P, Rc | Same week | |||||
| 12 | O | Rc | O | Wound | 4 weeks | |
| Rc | 2 weeks | |||||
| 13 | P | EA, P, Rc, U | P | Wound | Same week | |
| Urine | Same week | |||||
| 15 | R | EA | R | EA | Same week | |
| 16 | S1 | EA, P | S1 | EA | 2 weeks | |
| P | 1 week | |||||
| EA, P | Same week | |||||
| 17 | S2 | P | S2 | EA | 1 week | |
| EA, P | Same week | |||||
| 18 | U | EA | U | EA | Same week | |
| Uncorrelated cases | 2 | Sg | P | A | EA | Same week |
| Urine | 1 week | |||||
| 4 | D2 | Rc | C2 | Wound | 1 week and same week | |
| B2 | Rc | K2 | EA | Same week | ||
| 7 | Sg | Rc | I1 | EA | Same week | |
| 12 | Sg | Rc | O | Wound | Same week | |
| 16 | T | Rc | S1 | EA | Same week | |
| 17 | W | Rc | S2 | EA | Same week |
A-W – ERIC-PCR strain (a number denotes a clone subtype), Sg unique strain, EA endotracheal aspirate, P pharynx, Rc – rectum, U urine
Prediction of clinical strain by screening sites according to diagnosis
| Diagnosis | Clinical clone | Concordant screening sites | Discordant screening sites | ||||||
|---|---|---|---|---|---|---|---|---|---|
| EA | P | Rc | U | EA | P | Rc | U | ||
| VAP | A | + | + | + | + | ||||
| K2 | + | + | |||||||
| E1 | + | + | |||||||
| I1 | + | + | + | ||||||
| R | + | + | |||||||
| S1 | + | + | + | ||||||
| S2 | + | + | + | ||||||
| U | + | + | + | ||||||
| Screen site utility for VAP (%) | 7/8 (87) | 6/8 (75) | 4/8 (50) | NA | NA | 1/8 (12) | 4/8 (50) | NA | |
| SSI | B1 | + | + | ||||||
| C2 | + | ||||||||
| O | + | + | |||||||
| P | + | + | + | + | |||||
| Screen site utility for SSI (%) | 2/4 (50) | 2/4 (50) | 2/4 (50) | 1/4 (25) | NA | NA | 2/4 (50) | NA | |
| BSI | G | + | + | + | |||||
| IAI | D1 | + | |||||||
| Screen site utility for all infections (%) | 10/14 (71) | 9/14 (64) | 8/14 (57) | 1/14 (7) | NA | 1/14 (7) | 6/14 (43) | NA | |
VAP ventilator associated pneumonia, SSI surgical site infection, BSI blood stream infection, IAI intraabdominal infection, EA endotracheal aspirate, P pharynx, Rc rectum, U urine